AVAI (Avai Bio) Cyclically Adjusted PB Ratio: (As of Jul. 01, 2026)


AVAI Avai Bio Inc AVAI
24 GF Score
Price $0.15
! 3 Warning Signs
View Full Analysis

What is Avai Bio Cyclically Adjusted PB Ratio?

Avai Bio does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Avai Bio  (OTCPK:AVAI) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Avai Bio Cyclically Adjusted PB Ratio Related Terms


Avai Bio Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Avai Bio's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avai Bio Cyclically Adjusted PB Ratio Chart

Avai Bio Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Avai Bio Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AVAI vs IPM, RCT, LPSN: Cyclically Adjusted PB Ratio Comparison

For the Software - Application subindustry, Avai Bio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avai Bio Cyclically Adjusted PB Ratio vs Software Industry

For the Software industry and Technology sector, Avai Bio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Avai Bio's Cyclically Adjusted PB Ratio falls into.


AVAI
24GF Score
Avai Bio Inc AVAI
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avai Bio Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Avai Bio does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.


Avai Bio Business Description

Address 5348 Vegas Drive, Las Vegas, NV, USA, 89108
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score

Get the complete analysis for AVAI

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price